<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01458197</url>
  </required_header>
  <id_info>
    <org_study_id>TFN-KD01</org_study_id>
    <nct_id>NCT01458197</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.</brief_title>
  <official_title>A Prospective, Multi-center, Placebo-controlled, Randomized, Double-blind, Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo Administered as Oral Daily Dose for Three Months in Patients Suffering From Overactive Bladder.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kwang Dong Pharmaceutical co., ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kwang Dong Pharmaceutical co., ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Primary Objective:

           To evaluate the dose-response relationship of tarafenacin on efficacy.

        2. Secondary Objectives:

             -  To compare 12 weeks' efficacy of different doses of tarafenacin to that of placebo
                in patients suffering from Overactive Bladder. .

             -  To compare the tolerability of different doses of tarafenacin to that of placebo in
                patients suffering from Overactive Bladder. .
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the change in the number of micturitions per 24 hours from baseline to the end of the 12 weeks treatment period</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to 12weeks in Number of urgency episodes</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to 12weeks in Number of incontinence episodes</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to 12weeks in Number of nocturia episodes</measure>
    <time_frame>12weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to 12weeks in Volume of urine passed per void</measure>
    <time_frame>12weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to 12weeks in score of King's Health Questionnaire</measure>
    <time_frame>12weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">235</enrollment>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>Tarafenacin 0.2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tarafenacin 0.4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tarafenacin 0.2 mg</intervention_name>
    <description>Capsule, qd, 12 weeks</description>
    <arm_group_label>Tarafenacin 0.2 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule, qd, 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tarafenacin 0.4 mg</intervention_name>
    <description>Capsule, qd, 12 weeks</description>
    <arm_group_label>Tarafenacin 0.4 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        &lt; Inclusion Criteria&gt;

          1. Patient of either sex aged 20 to 80 years (both inclusive);

          2. Patients suffering from Overactive Bladder. based on cardinal symptoms (urgency,
             nocturia, frequency with or without urge incontinence) for at least 6 months prior to
             inclusion;

          3. Patients who document the following symptoms in a 3-day diary card during the 14 day
             placebo run-in period

               -  An average of ≥8 micturitions/24 hours;

               -  Greater than or equal to three incontinence episodes

               -  A total of ≥3 urgency episodes.

        &lt;Exclusion Criteria&gt;

          1. Patients with Clinically significant bladder outlet obstruction

          2. Patients with predominant stress incontinence (&gt;2 episode/week)

          3. Patients with significant urogenital disease such as recurrent urinary tract infection
             (more than 2/6 months), bladder calculi, interstitial cystitis, urothelial tumours,
             hysterectomy or prostatectomy in the previous six months;

          4. Females diagnosed with bladder cancer

          5. Males diagnosed with bladder cancer

          6. Patients with obstructive disease of the gastrointestinal tract, intestinal
             inflammatory disease, severe ulcerative colitis, inflammatory bowel disease, toxic
             megacolon, intestinal atony or paralytic ileum

          7. Patients with acute Noehyeolgwangye disease, significant Cardiovascular Disease
             (arrhythmias, unstable angina pectoris, myocardial infarct, or are using a pacemaker),
             significant Orthostatic hypotension in the previous six months

          8. Patients diagnosed with closed angle glaucoma or shallowness of the anterior chamber

          9. Patients with any contraindication to antimuscarinic drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myung-Soo Choo, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2011</study_first_submitted>
  <study_first_submitted_qc>October 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2011</study_first_posted>
  <last_update_submitted>March 11, 2014</last_update_submitted>
  <last_update_submitted_qc>March 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Overactive Bladder</keyword>
  <keyword>Tarafenacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

